Background
==========

Essential hypertension (EH) is one of the most important modifiable risk factors for cardiovascular disease (CVD) and renal disease in worldwide. In China, there is a prevalence estimate of 27.9%, or 133 million, hypertensive adults \[[@B1]\]. Hypertension is also a major risk factor for the development of CVD and renal morbid- and fatal events \[[@B2]\].

The etiology of hypertension is not well understood because it can be caused by single or multiple genetics, and also associated with environmental and other individual factors. Of the genetic factors, maternal transmission of hypertension has been implicated in some pedigrees, suggesting that mutations in mitochondrial DNA (mtDNA) may contribute to the pathogenesis of EH \[[@B3]-[@B7]\]. More recently, several mtDNA point mutations have been proved in association with hypertension. These mutations include T3308C in *ND1*\[[@B8]\], A4435G in tRNA^Met^\[[@B9]\], A4295G and A4263G in tRNA^Ile^\[[@B10],[@B11]\], and A4401G in tRNA^Met^ and tRNA^Gln^\[[@B12]\].

To identify novel mtDNA mutations involved in the pathogenesis of hypertension in Chinese population, we initiated a systematic and extended mutational screening of mtDNA in a large cohort of hypertension subjects from the Geriatric Cardiology Clinic at the Chinese PLA General Hospital. Here, we reported a novel point mutation C4329G in tRNA^Ile^ and tRNA^Gln^ genes carried by a Chinese Han family with maternally inherited hypertension.

Methods
=======

Subjects
--------

As part of a genetic screening program for hypertension, a Chinese Han family with maternal inherited hypertension was found at the Institute of Geriatric Cardiology at the Chinese PLA General Hospital. An experienced physician measured the systolic and diastolic blood pressures of subjects with a mercury column sphygmomanometer using a standard protocol. The first and the fifth Korotkoff sounds were taken to be indicative of systolic and diastolic blood pressures, respectively. The average of three such readings was taken as the examination blood pressure. Hypertension was defined according to the recommendation of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (JNC VI) \[[@B13]\] as a systolic blood pressure of 140 mmHg or higher and /or a diastolic blood pressure of 90 mmHg or greater. All the members of this family underwent a thorough physical examination, a laboratory assessment of CVD risk factors, and routine electrocardiography (Figure [1](#F1){ref-type="fig"}). All subjects were evaluated to identify both personal and medical histories of hypertension and other clinical abnormalities. DNA samples of the family and 366 healthy controls were aquired for sequence analysis. Informed consents were obtained from all participating members, under protocols approved by the ethics committee of the Chinese PLA General Hospital.

![**Pedigree chart of the Chinese family with hypertension.** Affected individuals are indicated by filled symbols. Arrowhead denotes proband.](1471-2350-15-84-1){#F1}

mtDNA sequencing and analysis
-----------------------------

Genomic DNA was isolated from whole blood cells of participants using Puregene DNA Isolation Kits (Gentra Systems, Minneapolis, MN). The entire mitochondrial genome of all the participants were PCR-amplified in 24 overlapping fragments using sets of light-strand and heavy-strand oligonucleotide primers \[[@B14]\]. Each fragment was purified and subsequently analyzed by direct sequencing in an ABI 3700 automated DNA sequencer (Applied Biosystems, Inc., Foster City, CA) using the Big Dye Terminator Cycle sequencing reaction kit. The resultant sequence data were compared with the revised consensus Cambridge sequence (GenBank accession no. NC-012920) \[[@B15]\]. All mtDNA mutations were individually analyzed using the MitoAnalyzer (National Institutes of Standards and Technology, Gaithersburg, MD; <http://www.cstl.nist.gov/biotech/strbase/mitoanalyzer.html>) and the MITOMAP database \[[@B16]\]. The haplogroups were deduced by comparing the complete mtDNA sequence data with previously reported haplogroup-specific variants \[[@B17]\].

Results
=======

Clinical presentation
---------------------

The proband (II-2) presented with essential hypertension with onset age of 50 years old. Her medical history reported a highest blood pressure reading of 220/120 mm Hg. She first underwent full evaluation at the Chinese PLA General Hospital Geriatric Cardiology Clinic at the age of 60 with a blood pressure 160/80 mm Hg. She suffered from headaches when her blood pressure exceeded 200/100 mmHg, and took oral reserpine and aspirin to prevent stroke when it ranged between 140/80 and 160/100 mmHg. She was diagnosed with diabetes mellitus two years ago for which she was administered oral metformin. Laboratory tests showed a normal range of liver function, normal cholesterol levels, and mild kidney dysfunction (creatinine clearance rate, 81.2 ml/min). Kidney dysfunction was secondary to hypertension. The ECG showed left ventricular hypertrophy. Physical examination revealed no other clinical abnormalities, including hyperlipidemia, vision and hearing impairments, and neurological disorders associated with mitochondrial DNA muation.

The proband's family located in Shanxi Province in Northern China (shown in Figure [1](#F1){ref-type="fig"}), the family presented with a maternal inheritance of hypertension. Her mother (I-2) was diagnosed with hypertension at 60 years of age, with a blood pressure of 180/100 mm Hg. She has three brothers and three sisters; one brother (II-13) and one sister (II-8) presented with high blood pressure at the age of 48 years and 55 years, respectively. One of her nieces (III-7) and one of her nephew (III-5) also had hypertension with an onset age of 43 and 40 years old. None of the offspring of the affected father had hypertension. The clinical data of other family members were showed in Table [1](#T1){ref-type="table"}.

###### 

Summary of clinical data of the members in the Chinese Pedigree

  **Subjects**    **Gender**   **Age of test(yrs)**   **Age of onset(yrs)**   **Systolic pressure(mmHg)**   **Diastolic pressure(mmHg)**   **IVST,mm(6-12 mm)**   **ECG**   **CCr(ml/min)**
  -------------- ------------ ---------------------- ----------------------- ----------------------------- ------------------------------ ---------------------- --------- -----------------
  II-1                M                 63                     \-                         132                            60                         10               N           89.1
  II-2\*              F                 60                     50                         160                            80                         12              LVH          81.2
  II-3                M                 61                     \-                         128                            68                         11               N           102.8
  II-4                F                 58                     \-                         120                            60                         10               N           103.5
  II-5                M                 68                     \-                         124                            58                         9                N           87.9
  II-6                F                 62                     \-                         130                            60                         10               N           86.5
  II-7                M                 70                     \-                         132                            70                         10               N           92.6
  II-8\*              F                 64                     55                         150                            80                         12              LVH          72.3
  II-9                M                 56                     \-                         128                            64                         9                N           82.3
  II-10               F                 52                     \-                         120                            66                         11               N           87.4
  II-11               M                 53                     \-                         124                            60                         10               N           92.7
  II-12               F                 50                     \-                         132                            68                         11               N           86.9
  II-13\*             M                 54                     48                         140                           100                         11               N           83.2
  II-14               F                 50                     \-                         128                            60                         9                N           119.2
  III-1               M                 40                     \-                         130                            60                         8                N           122.3
  III-2               M                 38                     \-                         128                            58                         8                N           130.2
  III-3               F                 35                     \-                         118                            60                         9                N           118.6
  III-4               M                 33                     \-                         120                            58                         9                N           108.6
  III-5               M                 40                     40                         150                            90                         12               N           89.1
  III-6               M                 39                     \-                         124                            60                         9                N           121.3
  III-7               F                 44                     43                         160                            90                         13              LVH          71.2
  III-8               M                 30                     \-                         116                            60                         8                N           114.5
  III-9               F                 28                     \-                         128                            70                         9                N           134.8
  III-10              M                 28                     \-                         126                            70                         9                N           107.9
  III-11              M                 25                     \-                         130                            70                         10               N           126.7
  III-12              F                 27                     \-                         120                            58                         9                N           139.6

\*These patients received antihypertension treatment. This table shows pretreatment blood pressures. CCr indicates endogenous creatinine clearance; F, female; M, male; IVST, interventricular septal thickness; LVH, ECG showed left ventricular hypertrophy; N, electrocardiography (ECG) was normal.

Mitochondrial DNA analysis
--------------------------

Since the transmission pattern of this family presented with maternal inherited hypertension, we supposed that mtDNA maybe involved in the pathogenesis. So we did further analyze on the mitochondrial genome of the family members. We did analyze on the entire mitochondrial gene using PCR amplification and subsequent sequence analysis of PCR fragments derived from proband II-2 and an unrelated Chinese control. As shown in Figure [2](#F2){ref-type="fig"}B, the point mutation C4329G in tRNA^Ile^ and tRNA^Gln^ genes was identified in the proband. Sequencing of the PCR fragment spanning the tRNA^Ile^ and tRNA^Gln^ genes revealed that this mutation was absent from 366 Chinese controls.

![**Identification and qualification of the 4329C \> G mutation at the junction between mitochondrial tRNA**^**Ile**^**and tRNA**^**Gln**^**genes. (A)** Schema of the location of 4329C \> G in the precursors of tRNA^Ile^ and tRNA^Gln^ genes. Cloverleaf structures of human mitochondrial tRNA^Ile^ and tRNA^Gln^ are derived from Florentz et al. \[[@B4]\]. Processing sites in the mitochondrial tRNA^Ile^ and tRNA^Gln^ precursors were determined for RNase Z. Arrow indicates the position of the 4329C \> G mutation. **(B)** Partial sequence chromatograms of tRNA^Ile^ and tRNA^Gln^ genes from an affected individual (II-2) and a married-in control (II-1). Arrow indicates the location of the base changes at position 4329.](1471-2350-15-84-2){#F2}

And all the family members had did sequence analysis. All the 14 maternal lineage except the pedigree (I-2), carried the C4329G mutation in tRNA^Ile^ and tRNA^Gln^ genes. The other non-maternal members had no this point mutation. And in these 14 maternal members, there are 5 of them had presented with hypertension. More important, her nieces (III-7) and nephew (III-5) also had hypertension with an onset age of 43 and 40 years old, respectively. And it is very important that none of the offspring of the affected father carried this point muation. We also did segregation analysis on the pedigree, and except for autosomal recessive, autosomal dominant, X-linked patterns. By far the mitochondrial point mutation is the most likely explanation of etiology of hypertension for this pedigree.

The C4329G mutation, as shown in Figure [2](#F2){ref-type="fig"}A, is located at the 3' end of the acceptor arm of tRNA^Ile^ and tRNA^Gln^\[[@B4],[@B18]\]. Figure [3](#F3){ref-type="fig"} presented us that the cytosine residue at this position is highly conserved in all known tRNA^Ile^ and tRNA^Gln^ sequences \[[@B4],[@B18]\]. In fact, nucleoside modifications at this position play a pivotal role in the stabilization of the tertiary structure and the tRNAs' function \[[@B19]\]. The C4467A mutation in tRNA^Met^ gene which was evolutionary conserved, but was not detected in other maternal members.

![**Alignment of tRNA**^**Ile**^**genes from different species.** Arrow indicates the position of the Acc-stem 71 at the anticodon loop of tRNA, corresponding to the C \> G at position 4329.](1471-2350-15-84-3){#F3}

To further identify the phenotypic manifestation, DNA fragments spanning the entire mtDNA of the proband II-2 were PCR-amplified. Each fragment was purified and subsequently analyzed by direct sequencing. As shown in Table [2](#T2){ref-type="table"}, a comparison of the resultant sequences with the Cambridge consensus sequence and control subject identified a number of nucleoside changes belonging to the Eastern Asian haplogroup H2 \[[@B20]\]. These included eight polymorphisms in the D-loop region, three variants in the 12S rRNA gene, one in the 16S rRNA gene, two in the *ND1* gene, a C4329G mutation in the tRNA^Ile^ and tRNA^Gln^ genes, one variant in the *COII* gene, one in the *COIII* gene, one in each of the ATPase6 and ATPase8 genes, two in the each of the *ND3* and *ND4* genes, and four in each of the *ND6* and *Cytb* genes \[[@B21]\]. Those tRNA, rRNA, and polypeptide variants were further evaluated by phylogenetic analysis of sequences from other organisms such as mouse \[[@B22]\], cow \[[@B23]\] and *Xenopus laevis*\[[@B24]\]. However, none of the polypeptide variants were highly conserved evolutionarily, indicating that they do not have a significant functional consequence.

###### 

**mtDNA variants in 1 Han Chinese subject** (**II**-**2**) **with hypertension and 1 Han Chinese control subject**

  **Gene**    **Position**   **Replacement**   **Conservation(H/M/B/X)\***   **rCRS**^**†**^   **II-2**   **Control**   **Previously reported**^**‡**^   **Amino acid change**
  ---------- -------------- ----------------- ----------------------------- ----------------- ---------- ------------- -------------------------------- -----------------------
  D-loop           73            A to G                                             A             G            G                      Y                             
                  152            T to C                                             T             C            C                      Y                             
                  263            A to G                                             A             G            G                      Y                             
                  310            T to C                                             T             C            C                      Y                             
                  489            T to C                                             T             C            C                      Y                             
  12SrRNA         1382           A to C                  A/G/G/C                    A             C            C                      Y                          rRNA
                  1438           A to G                  A/A/C/A                    A             G            G                      Y                          rRNA
  16SrRNA         2706           A to G                  A/G/G/A                    A             G            G                      Y                          rRNA
                  3010           G to A                  G/T/G/A                    G             A            A                      Y                          rRNA
  ND1             3975           C to T                  C/C/A/C                    C             T            C                      Y                           syn
                  4260           C to T                  C/M/C/T                    C             T            T                      Y                           syn
  tRNA Ile        4329           C to G                  C/C/C/C                    C             G            C                      N                             
  tRNA Met        4467           C to A                  C/C/C/C                    C             A            C                      N                             
  COII            8020           G to A                  G/P/C/A                    G             A            A                      Y                           syn
  ATPase8         8414           C to T                  C/A/C/A                    C             T            T                      Y                           L-F
  ATPase6         8701           A to G                  A/I/F/T                    A             G            G                      Y                           T-A
  COIII           9824           T to A                  T/F/L/C                    T             A            A                      Y                           syn
  ND3            10398           A to G                  A/E/E/A                    A             G            G                      Y                           T-A
                 10400           C to T                  C/I/T/E                    C             T            T                      Y                           syn
  ND4            10873           T to C                  T/T/T/C                    T             C            C                      Y                           syn
                 11984           T to A                  T/A/S/T                    T             A            T                      Y                           Y-H
  ND6            14580           A to T                                             A             T            T                      Y                           syn
                 14587           A to C                                             A             C            C                      Y                           syn
                 14605           A to G                                             A             G            G                      Y                           syn
                 14668           C to T                                             C             T            T                      Y                           syn
  Cytb           14783           T to C                  T/F/K/A                    T             C            C                      Y                           syn
                 15043           G to A                                             G             A            A                      Y                           syn
                 15301           G to A                                             G             A            A                      Y                           syn
                 15326           A to G                  A/L/S/A                    A             G            G                      Y                           T-A
  D-loop         16223           C to T                                             C             T            T                      Y                             
                 16311           T to C                                             T             C            C                      Y                             
                 16362           T to C                                             T             C            C                      Y                             

\*Data show the conservation of amino acid for polypeptides or nucleotide for rRNAs, in human (H), mouse (M), bovine (B), and Xenopus laevis (X).

^†^Cambridge sequence.

^‡^See <http://www.mitomap.org>.

Discussion
==========

EH is currently regarded as a multifactorial CVD, which may be influenced by both genetic and/or environmental factors. The role of genetic factors in the etiology of hypertension is improved by cross-sectional studies of familial aggregation of the disorder despite exposure to different environmental factors \[[@B10],[@B25]\]. Estimates of genetic variance range from 20--50% \[[@B26]\], and significant blood pressure correlations between mothers and offspring or excess maternal transmission of hypertension have been noted in several earlier \[[@B8],[@B25]\] and more recent \[[@B8]-[@B12]\] investigations.

In this study, we performed the clinical, genetic molecular investigation of a Chinese family with hypertension. Hypertension as a sole clinical phenotype was only presented in all matrilineal relatives of this three-generation pedigree, suggesting that the mtDNA mutation (s) is involved in this disorder. Mutational analysis of the mitochondrial genome identified the novel mutation 4329C \> G in tRNA^Ile^ and tRNA^Gln^ in matrilineal relatives of this Chinese family. The absence of this mutation from 366 Chinese controls strongly suggests that it is involved in the pathogenesis of hypertension. There are 32 variants identified belonging to the Eastern Asian haplogroup H2 on the maternal lineage. Thirty variants were the known polymorphisms, 4329C \> G and 4467C \> A were novel variants, but 4467C \> A were not identified in other maternal members (not detected in II-8, II-13). The 4329C \> G is located in the acceptor arm of tRNA^Ile^ and tRNA^Gln^, which is a 7-base pair stem made by the base pairing of the 5′-terminal nucleotide with the 3′-terminal nucleotide. This contains the CCA 3′-terminal group that is used to attach the amino acid. Pre-tRNA 3' ends are subsequently completed by the addition of the CCA triplet, and a subset of nucleotides becomes post-transcriptionally modified. Finally, mature and correctly folded tRNAs are esterified at the 3' end with the cognate amino acid by the corresponding aminoacyl-tRNA synthetase. These are subsequently transported to the ribosome by the translation factor elongation factor (EF)-Tu, enabling protein synthesis to occur. In addition, 4329 was located at the cleavage sites of tRNAase Z, so this substitution could impair (or not) the cleavage and processing of the policistronic mtRNA transcripts into mature mt-tRNA species. Thus, 3' end metabolism is important for both tRNA synthesis and function, as shown by a previous report by Guan et al. in which a Chinese family with Leber's hereditary optic neuropathy was found to be associated with the homoplasmic A15951G mutation located adjacent to the 3' end \[[@B27]\].

Conclusions
===========

In summary, the occurrence of the 4329C \> G mutation in the Chinese Han family pedigree with hypertension and its absence in 366 Chinese controls and the observed mitochondrial dysfunctions in cells carrying the mutation suggest that it is involved in the pathogenesis of hypertension. However, as hypertension is a complex CVD associated with multiple genetic and environmental factors, disease pathogenesis may result from this point mutation in association with other modifier factors.
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